0001209191-22-059438.txt : 20221202
0001209191-22-059438.hdr.sgml : 20221202
20221202170032
ACCESSION NUMBER: 0001209191-22-059438
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221201
FILED AS OF DATE: 20221202
DATE AS OF CHANGE: 20221202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bellinger Andrew
CENTRAL INDEX KEY: 0001864116
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 221442825
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-01
0
0001840574
Verve Therapeutics, Inc.
VERV
0001864116
Bellinger Andrew
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
0
1
0
0
CSO & CMO
Common Stock
2022-12-01
4
S
0
865
22.95
D
6629
D
Represents shares acquired pursuant to the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on November 30, 2022 in a transaction exempt pursuant to Rule 16b-3(c). The shares were automatically sold through an automatic sale program in which the Reporting Person elected to participate on May 1, 2022. The sale does not represent a discretionary trade by the Reporting Person.
/s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
2022-12-02